公开(公告)号：EP1431285A1

公开(公告)日：2004-06-23

申请号：EP02767899.4

申请日：2002-09-05

申请人： Kaken Pharmaceutical Co., Ltd.

发明人： SHIMANO, M., C.R.L. KAKEN PHARMACEUTICAL CO., LTD ,  KAMEI, N., C.R.L. KAKEN PHARMACEUTICAL CO., LTD ,  TANAKA, T., C.R.L. KAKEN PHARMACEUTICAL CO., LTD ,  HARADA, T., C.R.L. KAKEN PHARMACEUTICAL CO., LTD ,  HAINO, M., C.R.L. KAKEN PHARMACEUTICAL CO., LTD ,  OKUYAMA, A., C.R.L. KAKEN PHARMACEUTICAL CO., LTD ,  ARAKAWA, Y., C.R.L. KAKEN PHARMACEUTICAL CO., LTD ,  MURAKAMI, Y., C.R.L. KAKEN PHARMACEUTICAL CO., LTD

IPC分类号： C07C317/40 ,  C07D213/30 ,  C07D215/14 ,  C07D317/72 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D491/113

CPC分类号： C07D409/12 ,  C07C317/28 ,  C07C2601/14 ,  C07D207/20 ,  C07D211/70 ,  C07D213/30 ,  C07D213/42 ,  C07D215/14 ,  C07D277/14 ,  C07D317/72 ,  C07D319/06 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12

摘要： Reverse hydroxamic acid derivatives having specific structure represented by a general formula (Ia):
(wherein A is a hydrogen atom or the like; Ar 1 is an arylene or the like; Ar 2 is an optionally substituted aryl, a heteroaryl or the like; R 1 is a hydrogen atom, an alkyl or the like; R 2a is a substituted cycloaryl, a heterocycloaryl or the like) and a general formula (I):
(wherein A, Ar 1 , Ar 2 , and R 1 are the same as defined above and R 2 is an hydrogen atom, R 2a or the like) and salts thereof, which have TNF-α converting enzyme (TACE) inhibitory activity.